Public Financing and Delivery of HIV/AIDS Care: Securing the Legacy of Ryan White

Public Financing and Delivery of HIV/AIDS Care: Securing the Legacy of Ryan White

Volumn , Issue , 2005, Pages 1-358

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024089517     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/10995     Document Type: Book

References (449)

1. Aldridge C, Doyle A. 2002. Issue Brief: AIDS Drug Assistant Programs: Getting the Best Price? National ADAP Monitoring Project. Washington, DC: Kaiser Family Foundation. Pp. 1-8.
2. Andersen R, Bozzette S, Shapiro M, St. Clair P, Morton S, Crystal S, Goldman D, Wenger N, Gifford A, Leibowitz A, Asch S, Berry S, Nakazono T, Heslin K, Cunningham W. 2000. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research 35:389-416.
3. Bangsberg DR, Perry S, Charlesbois ED, Clark RA, Robertson M, Zolopa AR, Moss A. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9):1181-1183.
4. Bartlett J. 2002. Medical Management of HIV Infection, 2001-2002. Baltimore: Johns Hopkins University School of Medicine.
5. CDC (Centers for Disease Control and Prevention). 1994. HIV/AIDS Surveillance Report, 1993 5(4). Atlanta, GA: CDC.
6. CDC. 1998. Report of the NIH panel to define principles of therapy of HIV infection. MMWR 47(RR-5):1-41. [Online]. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00052295.htm [accessed July 12, 2002].
7. CDC. 2002. HIV/AIDS Surveillance Report, 2001 Year-End Edition 13(2). Atlanta, GA: CDC.
8. Celentano D, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE. 2001. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15(13):1707-1715.
9. CMS (Center for Medicare & Medicaid Services). 1999. Fact Sheet on Experienced HIV/ AIDS Providers 9/30/99. [Online]. Available: www.cms.hhs.gov/statee/letters [accessed July 12, 2002].
10. Conviser R, Murray M, Lau D. 2000. Medicaid managed care reimbursement for HIV and its implications for access to care. American Journal of Managed Care 6(9):990-999.
11. Cunningham WE, Andersen R, Katz M, Stein M, Turner B, Crystal S, Zierler S, Kuromiya K, Morton S, St Clair P, Bozzette S, Shapiro M. 1999. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Medical Care 37(12):1270-1281.
12. DHHS (U.S. Department of Health and Human Services). 2000. AIDS Drug Assistance Program Cost Containment Strategies. OEI-05-99-00610. Washington, DC: DHHS Office of Inspector General.
13. DHHS. 2001. Cost Containment of Medicaid HIV/AIDS Drug Expenditures. OEI-05-99- 00611. Washington, DC: DHHS Office of Inspector General.
14. Etheredge L, Moore J. 2003. A new Medicaid program: A proposal for a new state-federal partnership that bridges some large gaps in eligibility and coverage among the states. Health Affairs-Web Exclusive: W3-426-W3-439.
15. Fleming PL, Wortley PM, Karon JM, DeCock KM, Janssen RS. 2000. Tracking the HIV epidemic: Current issues, future challenges. American Journal of Public Health. 90(7):1037-1041.
16. GAO (General Accounting Office). 2000. Federal Drug Discounts. GAO/T-HEHS-00-118. Washington, DC: GAO.
17. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30(1):105-110.
18. Grant RM, Hecht FM, Warmerdam M, Liu L, Leigler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association 288(2):181-188.
19. Harrigan PR, Dong WY, Alexander C, Yip B, Ting L, Wynhoven B, Woodward J, Mo T, Hogg R, Montaner J. 2003. The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naïve individuals starting triple therapy. The 2nd International AIDS Society Conference on HIV Patho- genesis and Treatment. Abstract no. LB12. [Online]. Available: http://www.ias.se/ abstract/show.asp?abstract_id=11066 [accessed September 28, 2003].
20. IOM (Institute of Medicine). 2000. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press.
21. IOM. 2002. Fostering Rapid Advances in Health Care: Learning from Systems Demonstration. Washington, DC: The National Academies Press.
22. IOM. 2003. Priority Areas for National Action: Transforming Health Care Quality. Washington, DC: The National Academies Press.
23. Kahn JG, Zhang X, Cross LT, Palacio H, Birkhead GS, Morin SF. 2002. Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the U.S. Public Health Reports 117(3):252-262.
24. Kaiser Commission on Medicaid and the Uninsured. 2001 Medicaid and Managed Care. Washington, DC: Kaiser Family Foundation.
25. Kates J. 2004. Financing HIV/AIDS Care: A Quilt with Many Holes. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Kaiser Family Foundation.
26. Levi J, Hidalgo J. 2001. Financing and Delivery of HIV Care. Minority Health Today: Mobilizing to Fight HIV/AIDS in the African-American Community. April 2001 Supplement: 33-43.
27. Levi J, Kates J. 2000. HIV: Challenging the health care delivery system. American Journal of Public Health 90(7):1033-1036.
28. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 347(6):385-394.
29. Lo W, MacGovern T, Bradford J. 2002. Association of ancillary services with primary care utilization and retention for patients with HIV/AIDS. AIDS Care 14 (Suppl 1):S45-S57.
30. McNabb JJ, Ross W, Abriola K, Turley C, Nightingale C, Nicolau D. 2001. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases 33(5):700-705.
31. MedPAC (Medicare Payment Advisory Commission). 2003. Assessing payment adequacy and updating payment for physician services. In: Report to the Congress: Medicare Payment Policy. Washington, DC: Medicare Payment Advisory Commission. Pp. 105-118.
32. Menges J, Beronja N, Murray M. 2002. CHCS managed care solutions forum preliminary findings (Powerpoint presentation). [Online.] Available: http://www.chcs.org/ InformedPurchasing/MedicaidPharmacyPrelim.PPT [accessed February 24, 2004].
33. Messeri PA, Abramson DM, Aidala AA, Lee F, Lee G. 2002. The impact of ancillary HIV services on engagement in medical care in New York City. AIDS Care 14 (Suppl 1):S15- S29.
34. Morin S, Sengupta S, Cozen M, Richards TA, Shriver MD, Palacio H, Kahn JG. 2002. Responding to racial and ethnic disparities in the use of HIV drugs: analysis of state policies. Public Health Reports 117(3):263-272.
35. NCHS (National Center for Health Statistics). 2001. National Vital Statistics Report 49(11).
36. Norton S, Zuckerman S. 2000. Trends in Medicaid physician fees. Health Affairs 19(4):222- 232.
37. Palacio H, Kahn JG, Richards TA, Morin ST. 2002. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Reports 117(3):233-251.
38. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1):21-30.
39. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. 1999. Variations in the care of HIVinfected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association 281(24):2305-2315.
40. Tuller D. 2001, November 6. HIV practices face grim financial times. The New York Times. p. F6.
41. U.S. Census Bureau. 2000. U.S. Census 2000. U.S. Bureau of the Census. Washington, DC.
42. Wells K, Klap R, Koike A, Sherbourne C. 2001. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. American Journal of Psychiatry 158(12):2027- 2032.
43. GAO (General Accounting Office). 1995. Ryan White CARE Act of 1990: Opportunities Are Available to Enhance Funding Equity. GAO/T-HEHS-95-91. Washington, DC: GAO.
44. GAO. 2000. HIV/AIDS: Use of Ryan White CARE Act and Other Assistance Grant Funds. Report to Congressional Requesters. GAO/HEHS-00-54. Washington, DC: GAO.
45. GPO (Government Printing Office). 2000. Ryan White CARE Act Amendments of 2000: Managers' statement of explanation. Congressional Record H8840-H8843. Washington, DC: GPO.
46. Heinrich J, Director, Health Care, Public Health Issues, General Accounting Office. 2000. Ryan White CARE Act: Opportunities to Enhance Funding Equity. Statement at the July 11, 2000, hearing of the Subcommittee on Health and Environment, Committee on Commerce, U.S. House of Representatives. GAO/T-HEHS-00-150. Washington, DC: GAO.
47. HRSA (Health Resources and Services Administration). 2001. The Ryan White CARE Act Fact Sheets. [Online]. Available: http://www.hab.hrsa.gov [accessed March 21, 2003].
48. Johnson D. 1990, April 9. Ryan White dies of AIDS; his struggle helped pierce myths. The New York Times. p. D10.
49. Kaiser Family Foundation. 2001. The AIDS Epidemic at 20 Years: The View from America. A National Survey of Americans on HIV/AIDS. Washington, DC: Kaiser Family Foundation.
50. Kates J. 2004. Financing HIV/AIDS Care: A Quilt with Many Holes. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Kaiser Family Foundation.
51. Nadel MV, Associate Director, National and Public Health Issues, General Accounting Office. 1995. Ryan White CARE Act: Access to Services by Minorities, Women, and Substance Abusers. Statement at the July 17, 1995, hearing of the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives. GAO/HEHS-95-212. Washington, DC: GAO.
52. Palen J. 2003. Legislative History of the Ryan White CARE Act. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Unpublished.
53. Amaro H. 1999. An expensive policy: the impact of inadequate funding for substance abuse treatment. American Journal of Public Health 89(5):657-659.
54. APHA (American Public Health Association). 2002. Adherence to HIV Treatment Regimens: Recommendations for Best Practices, Pp. 126-130. [Online]. Available: http:// www.apha.org/PPP/HIV/Best_Practices.pdf [accessed February 18, 2004].
55. Bangsberg DR, Hecht FM, Charlesbois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. 2000. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS 14(4):357-366.
56. Bangsberg DR, Perry S, Charlesbois ED, Clark RA, Robertson M, Zolopa AR, Moss A. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9):1181-1183.
57. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. 1983. Isolation of a T-lymphocyte retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599):868-871.
58. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. 2001. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15(11):1369-1377.
59. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. 2001. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry 58(8):721-728.
60. Bogart LM, Kelly JA, Catz SL, Sosman JM. 2000. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of Acquired Immune Deficiency Syndromes 23(5):396-404.
61. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF. 1998. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 339(26):1897-1904.
62. Brewer TF, Vlahov D, Taylor E, Hall D, Munoz A, Polk BF. 1988. Transmission of HIV-1 within a statewide prison system. AIDS 2(5):363-367.
63. Brunette MF, Mercer CC, Carlson CL, Rosenberg SD, Lewis BF. 2000. HIV-related services for persons with severe mental illness: policy and practice in New Hampshire community mental health. Journal of Behavioral Health Services & Research 27(3):347-353.
64. Carey MP, Carey KB, Kalichman SC. 1997. Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses. Clinical Psychology Review 17(3):271-291.
65. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. The Lancet 353:2093-2099.
66. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. 2000. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology 19(2):124-333.
67. CDC (Centers for Disease Control and Prevention). 1981. Pneumocystis pneumonia-Los Angeles. MMWR 30(21):1-3.
68. CDC. 1982a. Epidemiologic notes and reports update on Kaposi's sarcoma and opportunistic infections in previously healthy persons-United States. MMWR 31(22):294, 300-301. Atlanta, GA: CDC
69. CDC. 1982b. Opportunistic infections and Kaposi's sarcoma among Haitians in the United States. MMWR 31(26):353-354, 360-361. Atlanta, GA: CDC
70. CDC. 1982c. Current trends update on acquired immune deficiency syndrome (AIDS)- United States. MMWR 31(37):507-508, 513-514. Atlanta, GA: CDC.
71. CDC. 1982d. Current trends acquired immune deficiency syndrome (AIDS): precautions for clinical and laboratory staffs. MMWR 31(43):577-580. Atlanta, GA: CDC.
72. CDC. 1982e. Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. MMWR 31(48):644-646, 652. Atlanta, GA: CDC.
73. CDC. 1983. Acquired immunodeficiency syndrome (AIDS): precautions for health-care workers and allied professionals. MMWR 32(34):450-451. Atlanta, GA: CDC.
74. CDC. 1994. HIV/AIDS Surveillance Report, 1993 5(4):1-33. Atlanta, GA: CDC.
75. CDC. 1998a. Report of the NIH panel to define principles of therapy of HIV infection. MMWR 47(RR-5):1-41. Atlanta, GA: CDC.
76. CDC. 1998b. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 47(RR20):1-51. Atlanta, GA: CDC.
77. CDC. 1999. The Deadly Intersection Between TB and HIV. [Online]. Available: http:// www.cdc.gov/hiv/pubs/facts/hivtb.htm [accessed November 1, 2003].
78. CDC. 2002a. HIV/AIDS Surveillance Report, 2001 Year-End Edition 13(2). Atlanta, GA: CDC.
79. CDC. 2002b. Frequently Asked Questions and Answers About Coinfection with HIV and Hepatitis C Virus. [Online]. Available: http://www.cdc.gov/hiv/pubs/facts/ HIV-HCV_Coinfection.htm [accessed November 1, 2003].
80. CDC. July 28, 2003. HIV Diagnoses Climbing Among Gay and Bisexual Men. Press release. CDC Office of Communications. Atlanta, GA: CDC.
81. CDC. 2004. Cumulative AIDS Cases-Dot Maps. [Online]. Available at: http://www.cdc.gov/ hiv/graphics/dotmaps.htm [accessed July 21, 2005].
82. Celentano D, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE. 2001. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15(13):1707-1715.
83. Chesney MA. 2003. Adherence to HAART regimens. AIDS Patient Care and Standards 17(4):169-177.
84. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. 2000. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group (AACTG). AIDS Care 12(3):255-266.
85. Cheung RC, Hanson AK, Maganti K, Keeffe EB, Matsui SM. 2002. Viral hepatitis and other infectious diseases in a homeless population. Journal of Clinical Gastroenterology 34(4):476-480.
86. Chiasson MA, Berenson L, Li W, Schwartz S, Singh T, Forlenza S, Mojica BA, Hamburg MA. 1999. Declining HIV/AIDS mortality in New York City. Journal of Acquired Immune Deficiency Syndromes 21(1):59-64.
87. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. 2001. Problem drinking and medication adherence among persons with HIV infection. Journal of General Internal Medicine 16(2):83-88.
88. Cournos F, McKinnon K. 1997. HIV seroprevalence among people with severe mental illness in the United States: a critical review. Clinical Psychology Review 17(3):259-269.
89. Crepaz N, Marks G. 2001. Are negative affective states associated with HIV sexual risk behaviors? A meta-analytic review. Health Psychology 20(4):291-299.
90. Culhane DP, Gollub E, Kuhn R, Shpaner M. 2001. The co-occurrence of AIDS and homelessness: results from the integration of administrative databases for AIDS surveillance and public shelter utilization in Philadelphia. Journal of Epidemiology and Community Health 55(7):515-520.
91. D'Amore J, Hung O, Chiang W, Goldfrank L. 2001. The epidemiology of the homeless population and its impact on an urban emergency department. Academic Emergency Medicine 8(11):1051-1055.
92. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection durations. Journal of the American Medical Association 280(17):1497-1503.
93. DHHS (U.S. Department of Health and Human Services). 1999. Mental Health: A Report of the Surgeon General. Rockville, MD: DHHS, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; National Institutes of Health, National Institute of Mental Health.
94. DHHS. 2004. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. [Online]. Available: http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 [accessed April 15, 2004].
95. Ekstrand M, Crosby GG, Paul J, Martin K, Bangsberg D, Stall RD. 2002 (July 7-12). Psychological Distress, Not Alcohol or Drug Use, Associated With ART Non-Adherence. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.
96. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. 2003. Factors affecting patient adherence to highly active antiretroviral therapy. Annals of Pharmacotherapy 37(6):775-781.
97. Estrada AL. 2002. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Reports 117(Suppl. 1):S126-S134.
98. Fauci AS. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
99. FDA (Food and Drug Administration). 2003a, January 31. HHS Extends Use of Rapid HIV Test to New Site Nationwide. News release. FDA Press Office. Washington, DC.
100. FDA. 2003b, March 13. FDA Approves First Drug in New Class of HIV Treatments for HIV Infected Adults and Children With Advanced Disease. News Release. FDA Press Office. Washington, DC.
101. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30(1):105-110.
102. Gebo KA, Keruly J, Moore RD. 2003. Association of social stress, illicit drug use, and health benefits with nonadherence to antiretroviral therapy. Journal of General Internal Medicine 18(2):104-111.
103. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, Kaplan AH, Wenger NS. 2002. A prospective study of predictors of adherence to combination antiretroviral medication. Journal of General Internal Medicine 17(10):756-765.
104. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. 1999. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 13(13):1763- 1769.
105. Gottlieb MS. 2001. AIDS-past and future. New England Journal of Medicine 344(23):1788- 1791.
106. Grant RM, Hecht FM, Warmerdam M, Liu L, Leigler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association 288(2):181-188.
107. Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. 1999. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. Journal of Urban Health 76(4):468-480.
108. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287(5453):607-614.
109. Hammett TM, Harmon MP, Rhodes W. 2002. The burden of infectious disease among inmates of and releasees from U.S. correctional facilities, 1997. American Journal of Public Health 92(11):1789-1794.
110. Harrigan PR, Dong WY, Alexander C, Yip B, Ting L, Wynhoven B, Woodward J, Mo T, Hogg R, Montaner J. 2003. The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naïve individuals starting triple therapy. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract no. LB12. [Online]. Available: http://www.ias.se/ abstract/show.asp?abstract_id=11066 [accessed September 28, 2003].
111. Haynes BF, Pantaleo G, Fauci AS. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271(5247):324-328.
112. Hinkin C, Castellon S, Lam MN, Hardy DJ, Stefaniak M, Farchione T, Ropacki M, Thrasher D, Mason K, Schug R, Durvasula RS. 2002 (July 7-12). Predictors of Medication Adherence in HIV/AIDS. Paper presented at the XIV International AIDS Conference, Barcelona, Spain. [Online]. Available at: http://www.aegis.com/conferences/14wac/ WePeB5828.html [accessed March 16, 2003].
113. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ. 1997. The National Depressive and Manic- Depressive Association consensus statement on the undertreatment of depression. Journal of the American Medical Association 277(4):333-340.
114. HIV/AIDS Treatment Information Service. 1999. Glossary of HIV/AIDS Related Terms. Third Edition. [Online]. Available: http://www.thebody.com/hivatis/glossary/contents.html [accessed March 11, 2003].
115. Holmberg SD. 1996. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. American Journal of Public Health 86(5):642-654.
116. Horsburgh CR Jr, Jarvis JQ, McArthur T, Ignacio T, Stock P. 1990. Seroconversion to human immunodeficiency virus in prison inmates. American Journal of Public Health 80(2):209-210.
117. HRSA (Health Resources and Services Administration). 1999. HRSA Care Action: HIV Disease in Women of Color. Rockville, MD: HRSA.
118. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. 2001. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996- 1999. Journal of Acquired Immune Deficiency Syndromes 28(4):345-350.
119. Ickovics JR, Meisler AW. 1997. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. Journal of Clinical Epidemiology 50(4):385-391.
120. IOM (Institute of Medicine). 1997. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Eng T, Butler W, eds. Washington, DC: National Academy Press.
121. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, Melnick S, Munoz A, for the Multicenter AIDS Cohort Study. 1999. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes 21(Suppl 1):S34-S41.
122. Johnson DL. 1997. Overview of severe mental illness. Clinical Psychology Review 17(3): 247-257.
123. Kahn JO, Walker BD. 1998. Acute human immunodeficiency virus type 1 infection. New England Journal of Medicine 339(1):33-39.
124. Kaiser Family Foundation. 2002 (November 13-15). HIV/AIDS and Other Sexually Transmitted Diseases (STDs) in the Southern Region of the United States: Epidemiological Overview. Paper presented at the Southern States Summit on HIV/AIDS and STDs: A Call to Action, Charlotte, NC.
125. Kalichman SC, Ramachandran B, Catz S. 1999. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. Journal of General Internal Medicine 14:276-273.
126. Karon JM, Fleming PL, Steketee RW, De Cock KM. 2001. HIV in the United States at the turn of the century: an epidemic in transition. American Journal of Public Health 91(7):1060-1068.
127. Kilbourne AM, Herndon B, Andersen RM, Wenzel SL, Gelberg L. 2002. Psychiatric symptoms, health services, and HIV risk factors among homeless women. Journal of Health Care for the Poor and Underserved 13(1):49-65.
128. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T. 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288(5472):1789-1796.
129. Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. 2001. Regular outpatient medical drug abuse care and subsequent hospitalization of persons who use illicit drugs. Journal of the American Medical Association 285(18):2355-2362.
130. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet 353:863-868.
131. Levi J., Hidalgo J. 2001. Financing and delivery of HIV care. Minority Health Today: Mobilizing to Fight HIV/AIDS in the African-American Community. April 2001 Supplement: 33-43.
132. Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, Zaidi AA, Farshy CE, Mitchell S, Talkington DF. 1998. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. Journal of Infectious Diseases 177(1):167- 174.
133. Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiological Reviews 57(1):183-289.
134. Lifson AR, Halcon LL. 2001. Substance abuse and high-risk needle-related behaviors among homeless youth in Minneapolis: implications for prevention. Journal of Urban Health 78(4):690-698.
135. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 347(6):385-394.
136. Liu H, Golin CE, Miller LG, Hays RD, Beck K, Sanandaji S, Christian J, Maldonado T, Duran D, Kaplan AH, Wenger NS. 2001. A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine 134(10):968-977.
137. Loue S, Oppenheim S. 1994. Immigration and HIV infection: a pilot study. AIDS Education and Prevention 6(1):74-80.
138. Lucas GM, Gebo KA, Chaisson RE, Moore RD. 2002. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16(5):767-774.
139. Malcolm SE, Ng JJ, Rosen RK, Stone VE. 2003. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 15(2):251-261.
140. Mannheimer S, Perkins M, Diamond B, Ford J, Holson N, Findley S, Colson P, El-Sadr W. 2002. (July 7-12). Predictors of Adherence to Antiretroviral Therapy in an Inner City Population. Paper presented at the XIV International AIDS Conference, Barcelona, Spain.
141. Markson LE, Houchens R, Fanning TR, Turner BJ. 1998. Repeated emergency department use by HIV infected persons: effect of clinic accessibility and expertise in HIV care. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17(1):35-41.
142. Martens WH. 2001. A review of physical and mental health in homeless persons. Public Health Reviews 29(1):13-33.
143. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. 2001. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases 33(5):700-705.
144. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272(5265):1167- 1170.
145. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126(12):946-954.
146. Metsch L, Pereyra M, Brewer TH. 2001. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. Journal of Substance Abuse Treatment 13(1-2):155-167.
147. Meyer I, Empfield M, Engel D, Cournos F. 1995. Characteristics of HIV-positive chronically mentally ill inpatients. The Psychiatric Quarterly 66(3):201-207.
148. Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. 2000. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 14(14):2129-2136.
149. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. 2004. Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal 170(2): 229-238.
150. Montoya ID, Bell DC, Richard AJ, Goodpastor WA, Carlson J. 1998. Barriers to social services for HIV-infected urban migrators. AIDS Education and Prevention 10(4): 366-379.
151. Murrill CS, Weeks H, Castrucci BC, Weinstock HS, Bell BP, Spruill C, Gwinn M. 2002. Agespecific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health 92(3):385-387.
152. NCHS (National Center for Health Statistics). 2001. National Vital Statistics Report 49(11).
153. NIC (National Intelligence Council). 2002. Next Wave of HIV/AIDS: Nigeria, Ethiopia, Russia, India, and China. Washington, DC: National Intelligence Council.
154. Nolan D. 2003. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63(23):2555-2574.
155. NRC (National Research Council). 1993. The Social Impact of AIDS in the United States. Jonsen AR, Stryker J, eds. Washington, DC: National Academy Press.
156. Ostrow D. 1999. Practical prevention issues. In: Ostrow D, Kalichman S, eds. Psychosocial and Public Health Impacts of New HIV Therapies. New York: Kluwer Academic/ Plenum.
157. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigator. New England Journal of Medicine 338(13):853-860.
158. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362(3418):355-358.
159. Pao M, Lyon M, D'Angelo LJ, Schuman WB, Tipnis T, Mrazek DA. 2000. Psychiatric diagnoses in adolescents seropositive for the human immunodeficiency virus. Archives of Pediatric & Adolescent Medicine 154(3):240-244.
160. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1):21-30.
161. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, Burki Z, Stanislawski D, Czerniewski MA, Garcia P. 1998. Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. American Journal of Cardiovascular Pathology 153(2):481-490.
162. Perry S, Bangsberg DB, Charlebois ED, Clark R, Karasic D, Dilley J, Sorensen J, Moss AR. 2002 (July 7-12). Depressive Symptoms Predict Adherence, Treatment Duration and Survival in an Urban Poor Cohort. Paper presented at the XIV International AIDS Conference, Barcelona, Spain. Abstract no. TuPeC4724.
163. Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles CM, Astemborski J. 1999. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(3):275-282.
164. Piliero PJ, Colagreco JP. 2003. Simplified regimens for treating HIV infection and AIDS. Journal of the American Academy of Nurse Practitioners 15(7):305-312.
165. Polk BF, Fox R, Brookmeyer R, Kanchanaraksa S, Kaslow R, Visscher B, Rinaldo C, Phair J. 1987. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. New England Journal of Medicine 316(2):61-66.
166. Quinn TC. 1997. Acute primary HIV infection. Journal of the American Medical Association 278(1):58-62.
167. Rabkin JG, Chesney M. 1999. Treatment adherence to HIV medications: the Achilles heel of the new therapeutics. In: Ostrow DG, Kalichman SC, eds. Psychosocial and Public Health Impacts of New HIV Therapies. New York: Kluwer Academic/Plenum.
168. Rich JD, Holmes L, Salas C, Macalino G, Davis D, Ryczek J, Flanigan T. 2001. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. Journal of Urban Health 78(2):279-289.
169. Rosenblum A, Nuttbrock L, McQuistion HL, Magura S, Joseph H. 2001. Hepatitis C and substance use in a sample of homeless people in New York City. Journal of Addictive Diseases 20(4):15-25.
170. Rothenberg RB, Wasserheit JN, St. Louis ME, Douglas JM. 2000. The effect of treating sexually transmitted diseases on the transmission of HIV in dually infected persons: a clinic-based estimate. Ad Hoc STD/HIV Transmission Group. Sexually Transmitted Diseases 27(7):411-416.
171. Sabin KM, Frey RL, Horsley R, Greby SM. 2001. Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998. Journal of Urban Health 78(2):241-255.
172. Samet JH, Freedberg KA, Stein MD, Lewis R, Savetsky J, Sullivan L, Levenson SM, Hingson R. 1998. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Archives of Internal Medicine 158(7):734-740.
173. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. 1998. Biological and virologic characteristics of primary HIV infection. Annals of Internal Medicine 128(8):613-620.
174. Seligmann M, Warrell DA, Aboulker JP, Carbon C, Darbyshire JH, Dormont J, Eschwege E, Girling DJ, James DR, Levy JP, Peto TEA, Schwarz D, Stone AB, Weller IVD, Withnall R, Gelmon K, Lafon E, Swart AM, Aber VR. 1994. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. The Lancet 343:871-881.
175. Sepkowitz KA. 2001. AIDS-the first 20 years. New England Journal of Medicine 344(23):1764-1772.
176. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. 1999. Variations in the care of HIVinfected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association 281(24):2305-2315.
177. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM. 1999. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clinical Infectious Diseases 29(4):824-830.
178. Smith MY, Rapkin BD, Winkel G, Springer C, Chhabra R, Feldman IS. 2000. Housing status and health care service utilization among low-income persons with HIV/AIDS. Journal of General Internal Medicine 15(10):731-738.
179. Solomon L, Stein M, Flynn C, Schuman P, Schoenbaum E, Moore J, Holmberg S, Graham NM. 1998. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17(3):253-261.
180. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. 2002. Human immunodeficiency virus in correctional facilities: a review. Clinical Infectious Diseases 35(3):305-312.
181. Spradling P. 2000 (July 9-14). Concurrent Use of Rifabutin and HAART: Evidence for Reduced Efficacy? Abstract TUOR B8277. XIII International AIDS Conference, Durban, South Africa.
182. Stone VE. 2002. Enhancing adherence to antiretrovirals: strategies and regimens. Medscape General Medicine 4(3). [Online]. Available: http://www.medscape.com/viewarticle/ 438193 [accessed June 21, 2003].
183. Stoskopf CH, Richter DL, Kim YK. 2001. Factors affecting health status in African Americans living with HIV/AIDS. AIDS Patient Care and STDS 15(6):331-338.
184. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. 2002. Hepatitis C and progression of HIV disease. Journal of the American Medical Association 288(2):199- 206.
185. Sullivan P, Nakashima A, Purcell DW, Ward JW. 1998. Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19(3):266-273.
186. Sullivan G, Koegel P, Kanouse DE, Cournos F, McKinnon K, Young AS, Bean D. 1999. HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Psychiatric Services 50(5):648-652.
187. Tucker JS, Kanouse DE, Miu A, Kogel P, Sullivan G. 2003. HIV risk behaviors and their correlates among HIV-positive adults with serious mental illness. AIDS and Behavior 7(1):29-40.
188. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, Stein MD, Longshore D, Bozzette SA. 2001. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine 16(9):625-633.
189. United Nations. 2003. World Population Prospects: The 2002 Revision. New York: Population Division, Department of Economic and Social Affairs, United Nations.
190. U.S. Census Bureau. 2000. U.S. Census 2000. Washington, DC: U.S. Bureau of the Census.
191. USPHS/IDSA (U.S. Public Health Service/Infectious Diseases Society of America) Prevention of Opportunistic Infections Working Group. 2001. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clinical Trials 2(6):493-554.
192. Vlahov D, Brewer F, Munoz A, Hall D, Taylor E, Polk BF. 1989. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987. Journal of Acquired Immune Deficiency Syndromes 2(3):283-290.
193. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, Lyles CM, Nelson KE, Smith D, Holmberg S, Farzadegan H. 1998. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. Journal of the American Medical Association 279(1):35-40.
194. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch MS. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer that 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine 322(14):941-949.
195. Weis SE, Moonan PK, Pogoda JM, Turk L, King B, Freeman-Thompson S, Burgess G. 2001. Tuberculosis in the foreign-born population of Tarrant county, Texas by immigration status. American Journal of Respiratory and Critical Care Medicine 164(6):953-957.
196. Welch K, Morse A. 2001. Survival patterns among HIV+ individuals based on health care utilization. Journal of the National Medical Association 93(6):214-219.
197. Wensing AMJ, van de Viver DAMC, Asjo B, Balotta C, Camacho R, de Luca A, de Mendoza C, Deroo S, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman A, Horban A, Korn K, Kuecherer C, Leitner T, Nielsen C, Ormasson V, Perrin L, Paraskevix D, Puchhammer E, Roman F, Ruiz L, Salminen M, Schmit JCC, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CAB. 2003. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: The CATCH-Study. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract no. LB01. [Online]. Available: http://www.ias.se/abstract/ show.asp?abstract_id=111122 [accessed September 28, 2003].
198. Wilson TE, Massad LS, Riester KA, Barkan S, Richardson J, Young M, Gurtman A, Greenblatt R. 1999. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Intergency HIV Study. AIDS 13(5):591-598.
199. AHRQ (Agency for Health, Research and Quality). 2004. HCSUS: HIV Cost and Services Utilization Study. Fact sheet. Rockville, MD: Agency for Health Care Policy and Research. [Online]. Available: http://www.ahrq.gov/data/hcsus.htm [accessed January 3, 2004].
200. Altice FL, Friedland GH. 1998. The era of adherence to HIV therapy. Annals of Internal Medicine 129(6):503-505.
201. APHA (American Public Health Association). 2002. Adherence to HIV Treatment Regimens: Recommendations for Best Practices. Pp. 126-130. [Online]. Available: http:// www.apha.org/PPP/HIV/Best_Practices.pdf [accessed March 14, 2004].
202. Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F. 2002. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials 3(1):52-57.
203. Ashman JJ, Conviser R, Pounds MB. 2002. Associations between HIV-positive individuals' receipt of ancillary services and medical care receipt and retention. AIDS Care 14(Suppl. 1):S109-S118.
204. Ashman JJ, Marconi KM, McKinney MM, O'Neill JF. 2000. Who receives Ryan White CARE Act Services? A demographic comparison of CARE Act clients and the general AIDS population. AIDS Patient Care STDS 14(10):561-565.
205. Bangsberg DR, Perry S, Charlesbois ED, Clark RA, Robertson M, Zolopa AR, Moss A. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9):1181-1183.
206. Barroso PF, Schecter M, Gupta P, Melo MF, Viera M, Murta FC, Sourza Y, Harrison LH. 2000. Effect of antiretroviral therapy on HIV shedding in semen. Annals of Internal Medicine 133(4):280-284.
207. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. 2001. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry 58(8):721- 728.
208. Bozzette S, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF. 1998. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 339(26):1897-1904.
209. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, Rastegar A, Timberlake D, Shapiro MF, Goldman DP. 2001. Expenditures for the care of HIVinfected patients in the era of highly active antiretroviral therapy. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 344(11):817-823.
210. Bruce RD, Altice FL. 2003. Editorial Comment. Why treat three conditions when it is one patient? AIDS Reader 13(8):375-382.
211. Buchanan RJ. 2002. Ryan White CARE Act and eligible metropolitan areas. Health Care Financing Review 23(4):149-157.
212. CDC (Centers for Disease Control and Prevention). 1998. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 47(RR-20):1-26.
213. CDC. 2003a. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR 52(15):329-332.
214. CDC. 2003b. Advancing HIV Prevention: The Science Behind the Initiative. [Online]. Available: http://www.cdc.gov/hiv/partners/ahp_science.htm [accessed October 14, 2003].
215. CDC. 2003c. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, Health Resources and Services Administration, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. MMWR 52(R12):1-24.
216. CDC. 2003d. Treatment of tuberculosis. Official statement of the American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 52(R11):1-77.
217. CMS (Centers for Medicare & Medicaid Services). 2002. Fact Sheet: Medicaid and Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection. [Online]. Available: http://cms.hhs.gov.hiv/hivfs.asp [accessed July 8, 2003].
218. CSAT (Center for Substance Abuse Treatment). 1995. Treatment for HIV-Infected Alcohol and other Drug Abusers: Treatment Improvement Protocol Series 15. DHHS Publication No. (SMA) 95-3038. Rockville, MD: Substance Abuse and Mental Health Services Administration.
219. CSAT. 2000. Substance Abuse Treatment for Persons with HIV/AIDS: Treatment Improvement Protocol Series 37. DHHS Publication No. (SMA) 00-3410. Rockville, MD: Substance Abuse and Mental Health Services Administration.
220. Cohn SE, Berk ML, Berry SH, Duan N, Frankel MR, Klein JD, McKinney MM, Rastegar A, Smith S, Shapiro MF, Bozzette SA. 2001. The care of HIV-infected adults in rural areas of the United States. Journal of Acquired Immune Deficiency Syndrome 28(4):385-392.
221. Conviser R, Pounds MB. 2002. The role of ancillary services in client-centered systems of care. AIDS Care 14(Suppl. 1):119-132.
222. DHHS (U.S. Department of Health and Human Services). 2004. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. [Online]. Available: http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 [accessed April 15, 2004].
223. Douaihy AB, Jou RJ, Gorske T, Salloum IM. 2003a. Triple diagnosis: dual diagnosis and HIV disease, part 1. AIDS Reader 13(7):331-341.
224. Douaihy AB, Jou RJ, Gorske T, Salloum IM. 2003b. Triple diagnosis: dual diagnosis and HIV disease, part 2. AIDS Reader 13(8):375-382.
225. Evans DL, Ten Have TR, Douglas SD, Genes DR, Morrison M, Chiappini MS, Brinker Spence P, Job C, Mercer DE, Wang YL, Cruess D, Dube B, Dalen EA, Brown T, Bauer R, Petitto JM. 2002. Association of depression with viral load, CD8 I lymphocytes, and natural killer cells in women with H infection. American Journal of Psychiatry 159(10):1752-1759.
226. Faragon JJ, Pilliero PJ. 2003. Drug interactions associated with HAART: focus on treatment for addiction and recreational drugs. AIDS Reader 13(9):433-450.
227. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. 1996. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. American Journal of Drug & Alcohol Abuse 22(4):475-487.
228. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. 2001. The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine 344(11):824-831.
229. Friedman SR, Curtis R, Neaigus A, Benny J, Des Jarlais DC. 1999. Social Networks, Drug Injectors' Lives, and HIV/AIDS. New York: Kluwer Academic/Plenum Publishers.
230. GAO (General Accounting Office). 2000. Ryan White CARE Act: Opportunities to Enhance Funding Equity. GAO/T-HEHS-00-150. Washington, DC: GAO.
231. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30(1):105-110.
232. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. 1999. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 13(8):963-999.
233. Gifford AL, Groessl EJ. 2002. Chronic disease self-management and adherence to HIV medications. Journal of Acquired Immune Deficiency Syndrome 31:S163-S166.
234. Goldman DP, Leibowitz AA, Joyce GF, Fleishman JA, Bozzette SA, Duan N, Shapiro MF. 2003. Insurance status of HIV-infected adults in the post-HAART era: evidence from the United States. Applied Health Economics and Health Policy 2(1):85-91.
235. Golub ET, Astemborski JA, Hoover DR, Anthony JC, Vlahov D, Strathdee SA. 2003. Psychological distress and progression to AIDS in cohort of injection drug users. Journal of Acquired Immune Deficiency Syndromes 32(4):429-434.
236. Harrigan PR, Dong WY, Alexander C, Yip B, Ting L, Wynhoven B, Woodward J, Mo T, Hogg R, Montaner J. 2003. The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naïve individuals starting triple therapy. The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Abstract no. LB12. [Online]. Available: http://www.ias.se/ abstract/show.asp?abstract_id=11066 [accessed September 28, 2003].
237. Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, McCaffery DF, Fleischman JA, Crystal S, Collins R, Eggan F, Shapiro MF, Bozzette SA. 2000. Healthrelated quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. American Journal of Medicine 108:714-722.
238. Hirsch MS, Bru-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobson DM, Richman DD. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Disease 37(1):113-128.
239. HRSA (Health Resources and Services Administration). 2001. Outcome Evaluation Technical Assistance Guide: Case Management Outcomes, Titles I and II of the Ryan White CARE Act. Rockville, MD: HRSA.
240. HRSA. 2002a. Title I: Grants to Eligible Metropolitan Areas. [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/title1fact.htm [accessed April 14, 2004].
241. HRSA. 2002b. Title II: AIDS Drug Assistance Program. [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/adap1.htm [accessed April 14, 2004].
242. HRSA. 2002c. Title II: Grants to States and Territories [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/titleiifact.htm [accessed April 14, 2004].
243. HRSA. 2002d. Title III: Capacity Building Grant Program. [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/titleiiicap.htm [accessed April 14, 2004].
244. HRSA. 2002e. Title IV Services or Women, Infants, Children, Youth, and their Families. [Online]. Available: http://hrsa.gov/hab/titleiv.htm [accessed April 14, 2004].
245. HRSA. 2002f. Dental Reimbursement Program. [Online]. Available: http://hab.hrsa.gov/ programs/factsheets/drpfact.htm [accessed April 14, 2004].
246. HRSA. 2002g. AIDS Education and Training Centers Program. [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/aetc.htm [accessed April 14, 2004].
247. HRSA. 2002h. Special Projects of National Significance Program. [Online]. Available: http:// hab.hrsa.gov/programs/factsheets/spnsfact.htm [accessed April 14, 2004].
248. HRSA. 2002j. Ryan White CARE Act Annual Administrative Report 2000: Title I, Title II, AIDS Drug Assistance Program, Health Insurance Program. Rockville, MD: HRSA.
249. HRSA. 2003a. Ryan White CARE Act Appropriations for Fiscal Years 1991-2003. [Online]. Available: ftp://ftp.hrsa.gov/hab/findinghis03.xls. [accessed April 14, 2004].
250. HRSA. 2003b. HRSA CARE ACTION: Prevention Is Treatment: Prevention with Positives in Clinical Care. [Online]. Available: ftp://ftp.hrsa.gov/hab/march2003.pdf [accessed April 27, 2004].
251. HRSA. 2003c. Title I Manual. [Online]. Available: http://hab.hrsa.gov/tools/title1/ [accessed October 29, 2003].
252. HRSA. 2003d. Title II Manual. [Online]. Available: http://hab.hrsa.gov/tools/title2/ [accessed October 29, 2003].
253. Hsu JH. 2002. Substance Abuse and HIV. The Hopkins HIV Report. [Online]. Available: http://www.Hopkins-aids.edu/publications/report/july02_5.html [accessed April 14, 2004].
254. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum BE, Schuman P, Boland RJ, Moore J, HIV Epidemiology Research Study Group. 2001. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. Journal of the American Medical Association 285(11):1466-1474.
255. IOM (Institute of Medicine). 1996. Primary Care: America's Health in a New Era. Donaldson MS, Yordy KD, Lohr KN, Vaneslow NA, eds. Washington, DC: National Academy Press.
256. IOM. 1999. Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States. Stoto MA, Almario DA, McCormick MC, eds. Washington, DC: National Academy Press.
257. IOM. 2001. No Time to Lose: Getting More from HIV Prevention. Ruiz MS, Gable AR, Kaplan EH, Stoto MA, Fineberg H, Trussell J, eds. Washington, DC: National Academy Press.
258. Kaiser Commission on Medicaid and the Uninsured. 2001. Medicaid: A Primer. Washington, DC: Henry J. Kaiser Family Foundation.
259. KFF (Kaiser Family Foundation). 2004. Medicare: Medicare at a Glance. Washington, DC: Kaiser Family Foundation.
260. Kalichman SC, Rompa D, Cage M, DiFonzo K, Simpson D, Austin J, Luke W, Buckles J, Kyomugisha F, Benotsch E, Pinkerton S, Graham J. 2001. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. American Journal of Preventive Medicine 21(2):84-92.
261. Kates J. 2004. Financing HIV/AIDS Care: A Quilt with Many Holes. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Kaiser Family Foundation.
262. Kates J, Levi J, Neal J, Gallagher K. 2002. Learning more about the HIV-infected population not in care in the United States: using public health surveillance data to inform current policy challenges in enhancing access. Poster TuPeG 5690, XIV International AIDS Conference, Barcelona, Spain.
263. Katz MH, Cunningham WE, Fleishman JA, Andersen RM, Kellogg T, Bozzette SA, Shapiro MF. 2001. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Annals of Internal Medicine 135(8 Pt. 1):557-565.
264. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. 2001. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 27:14-19.
265. Laine C, Markson LE, McKee LJ, Hauck WW, Fanning TR, Turner BJ. 1998. The relationship of clinical experience with advanced HIV and survival of women with AIDS. AIDS 12(4):417-424.
266. Lubinski C, Weddle A, Grayer C. 2002. Medicaid Financing of HIV care: An Analysis of Five State Programs. Paper prepared for the Committee on the Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Unpublished.
267. Lucas GM, Gebo KA, Chaisson RE, Moore RD. 2002. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16(5):767-774.
268. Magnus M, Schmidt N, Brown B, Kissinger PJ. 2002. A profile of an HIV- and child-specific programme in New Orleans, Louisiana, USA. AIDS Care 14(Suppl. 1):85-94.
269. Margolin A, Avants SK, Warbourton LA, Hawkins KA, Shi J. 2003. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychology 22(2):223-228.
270. Markson L, Houchens R, Fanning TR, Turner BJ. 1998. Repeated emergency department use by HIV infected persons: effect of clinic accessibility and expertise in HIV care. Journal of Acquired Immune Deficiency Syndromes 17(1):35-41.
271. McKinney MM, Marconi KM. 2002. Delivering HIV services to vulnerable populations: A review of CARE Act-funded research. Public Health Reports 117:99-113.
272. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. 2001. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases 33(5):700-705.
273. Messeri PA, Abramson DM, Aidala AA, Lee F, Lee G. 2002. The impact of ancillary HIV services on engagement in medical care in New York City. AIDS Care 14(Suppl. 1):15-29.
274. Moore RD. 2000. Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 17(4):325-330.
275. NIH (National Institutes of Health). 1997. Interventions to Prevent HIV Risk Behaviors. NIH Consensus Statement. [Online]. Available: http://consensus.nih.gov/cons/104/ 104_statement.htm [accessed April 27, 2004].
276. Otto-Salaj LL, Stevenson Y. 2001. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. AIDS Reader 11(4):197-208.
277. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. 2003. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes 32(5):522-526.
278. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1):21-30.
279. Pernice C, Wysen K, Riley T, Kaye N. 2001. Charting SCHIP: Report of the Second National Survey of the State Children's Health Insurance Program. Portland, ME: National Academy for State Health Policy.
280. Pollitz K, Tapay N, Hadley E, Specht J. 2000. Early experience with 'new federalism' in health insurance regulation. Health Affairs 19(4):7--22.
281. SAMHSA (Substance Abuse and Mental Health Services Administration). 1997. HIV/AIDS: Initial findings from the field. Information Center Bulletin 1(1). National Mental Health Information Center. [Online]. Available: http://www.mentalhealth.org/publications/ allpubs/KEN96-0040/ken96-0040-05.asp [accessed May 7, 2004].
282. Schietinger H, Schecter C. 1998. Medical Coverage for Medicare Beneficiaries with HIV/ AIDS: Issues and Implications. Washington, DC: Academy for Educational Development.
283. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. 1999. Variations in the care of HIVinfected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association 281(24):2305-2315.
284. Sherer R, Stieglits K, Narra J, Jasek J, Green L, Moore B, Short S, Cohen M. 2002. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care 14(Suppl. 1):31-44.
285. SSA (Social Security Administration). 2004. Supplemental Security Income (SSI): understanding Supplemental Security Income if You are Disabled or Blind. [Online]. Available: http://www.ssa.gov/notices/supplemental-security-income/text-disable-ussi.htm [accessed February 3, 2004].
286. Starace F, Anmassari A, Trotta MP, Murri R, Dc Longis P, Izzo C, Sca A, d'Arminio Monforte A, Wu AW, Antinori A; Ad Study Group; NeurolCoNa Study Group. 2002. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 31(Suppl 3):S136-S139.
287. Staszewski S, Morales-Ramires J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryler R, Johnson P, Labriola DF, Farina, D Manion DJ, Ruiz N, for the Study 006 Team. 1999. Efavirenz plus Zidouvudine and Lamivudine, Efavirenz plus Indavir, and Indavir plus Zidovudine and Lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 341(25):1865-1873.
288. Sternhell PS, Corr MJ. 2002. Psychiatric morbidity and adherence to antiretroviral medication in patients with FHV/AIDS. Australian & New Zealand Journal of Psychiatry 36(4): 528-533.
289. Tucker JS, Burnarn MA, Sherbourne CD, Kung FY, Gifford AL. 2003. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine 114(7):573-580.
290. U.S. Preventive Services Task Force. 1996. Guide to Clinical Preventive Services. 2nd ed. Washington, DC: U.S. Department of Health and Human Services.
291. U.S. Public Health Service Task Force. 2003. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Washington, DC: U.S. Department of Health and Human Services.
292. U.S. Public Health Service Task Force and Infectious Diseases Society of America. 2001. Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV. Washington, DC: U.S. Department of Health and Human Services.
293. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. 1999. Sexual transmission of HIV: infectiousness and prevention. AIDS 13(2):155-166.
294. Westmoreland T. 1999. Medicaid and HIV/AIDS Policy: A Basic Primer. Washington, DC: Henry J. Kaiser Family Foundation.
295. WGATMM (Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children). 2004, January 20. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. [Online]. Available: http://aidsinfo.nih.gov/guidelines/ pediatric/PED_012004.pdf [accessed April 15, 2004].
296. Adams EK. 2001. Factors affecting physician provision of preventive care to Medicaid children. Health Care Financing Review 22(4):9-26.
297. Andersen R, Bozzette S, Shapiro M, St. Clair P, Morton S, Crystal S, Goldman D, Wenger N, Gifford A, Leibowitz A, Asch S, Berry S, Nakazono T, Heslin K, Cunningham W. 2000. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HIV Cost and Services Utilization Study Consortium. Health Services Research 35(2):389-416.
298. Ashman DJ, Conviser R. 1998. HIV Capitation Risk Adjustments Conference Report. Menlo Park, CA: Kaiser Family Foundation.
299. Bartlett J. 2002. Medical Management of HIV Infection, 2001-2002. Baltimore, MD: Johns Hopkins University School of Medicine.
300. Beronja N, Menges J, Chang A, Murray M. 2002. Comparison of Medicaid Pharmacy Costs and Usage between the Fee-for-Service and Capitated Setting. Washington, DC: Center for Health Care Strategies, Inc.
301. Bhattacharya J, Goldman D, Sood N. 2003. The link between public and private insurance and HIV-related mortality. Journal of Health Economics 22:1105-1122.
302. Bozzette S, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF. 1998. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 339(26):1897-1904.
303. Brook RH, Ware JE Jr., Rogers WH, Keeler EB, Davies AR, Donald CA, Goldberg GA, Lohr KN, Masthay PC, Newhouse JP. 1983. Does free care improve adults' health? Results from a randomized controlled trial. New England Journal of Medicine 309(23):1426- 1434.
304. Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI. 1999. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clinical Infectious Disease 28:14-22.
305. Buchmueller T, DiNardo J. 1999. Did Community Rating Induce an Adverse Selection Death Spiral? Evidence from New York, Pennsylvania, and Connecticut. Working Paper 6872. [Online]. Available: http://www.nber.org/papers/w6872 [accessed March 8, 2004].
306. CMS (Center for Medicare and Medicaid Services). 1999. Fact Sheet on Experienced HIV/ AIDS Providers 9/30/99. [Online]. Available: www.cms.hhs.gov/statee/letters [accessed July 12, 2002].
307. Cohn SE, Berk ML, Berry SH, Duan N, Frankel MR, Klein JD, McKinney MM, Rastegar A, Smith S, Shapiro MF, Bozzette SA. 2001. The care of HIV-infected adults in rural areas of the United States. Journal of Acquired Immune Deficiency Syndrome 28(4):385-392.
308. Conviser R. 2002, February 22. Presentation to the Institute of Medicine Committee on the Public Financing and Delivery of HIV Care, Washington, DC.
309. Conviser R, Kerrigan D, Thompson S. 1997. The adequacy of reimbursement for HIV under section 1115 Medicaid waivers. AIDS Public Policy Journal 12(3):112-127.
310. Conviser R, Murray, M, Lau, D. 2000. Medicaid managed care reimbursement for HIV and its implications for access to care. American Journal of Managed Care 6(9):990-999.
311. Cook JA, Cohen MH, Grey D, Kirstein L, Burke JK, Anastos K, Palacio H, Richardson J, Wilson TE, Young M. 2002. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American Journal of Public Health 92(1):82-87.
312. Cunningham PJ. 2002. Mounting Pressures: Physicians Servicing Medicaid Patients and the Uninsured, 1997-2001. Health System Change Tracking Report No. 6. Washington, DC: Center for Studying Health Systems Change.
313. Cunningham WE, Andersen RM, Katz MH, Stein MD, Turner BJ, Crystal S, Zierler S, Kuromiya K, Morton SC, St. Clair P, Bozzette SA, Shapiro MF. 1999. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Medical Care 37(12):1270-1281.
314. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford A, Liu HH, Nakazono TT, Morton S, Bozzette SA, Shapiro MF, Wenger NS. 2000. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. Journal of Acquired Immune Deficiency Syndrome 25(2):115-123.
315. DHHS (U.S. Department of Health and Human Services). 1999. Mental Health: A Report of the Surgeon General. Rockville, MD: DHHS, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; National Institutes of Health, National Institute of Mental Health.
316. DHHS. 2001. Mental Health: Culture, Race and Ethnicity. A Report of the Surgeon General. Rockville, MD: DHHS, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; National Institutes of Health, National Institute of Mental Health.
317. Eichner J. 2001. Medicare Brief, Coordination of Health Coverage for Medicare Enrollees: A Case Study of HIV/AIDS. Washington, DC: National Academy of Social Insurance.
318. GAO (General Accounting Office). 2000. HIV/AIDS: Use of Ryan White CARE Act and Other Assistance Grant Funds. Report to Congressional Requesters. GAO/HEHS-00- 54. Washington, DC: GAO.
319. GAO. 2002. Medicare Physician Payments: Spending Targets Encourage Fiscal Discipline, Modifications Could Stabilize Fees. GA-02-441T. Washington, DC: GAO.
320. Gerbert B, Moe JC, Saag MS, Benson CA, Jacobsen DM, Feraios A, Hill ME, Bronstone A, Caspers N, Volberding PA. 2001. Toward a definition of HIV expertise: a survey of experienced HIV physicians. AIDS Patient Care STDs 15(6):321-330.
321. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, Shapiro MF, Bozzette SA. 2002. Participation in research and access to experimental treatment by HIV-infected patients. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 346(18):1373-1382.
322. HCFA (Health Care Financing Administration). 2000. A Profile of Medicaid: Chartbook 2000. Washington, DC: HCFA.
323. IOM (Institute of Medicine). 2003. Measuring What Matters: Allocation, Planning and Quality Assessment for the Ryan White CARE Act. Washington, DC: The National Academies Press.
324. Kahn JG, Haile B, Kates J, Chang S. 2001. Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. American Journal of Public Health 91(9):1464-1473.
325. Kaiser Commission on Medicaid and the Uninsured. 2001. Medicaid and Managed Care. Washington, DC: Kaiser Family Foundation.
326. Kaiser Family Foundation. 2002. Medicare + Choice Withdrawals: Understanding Key Factors. Washington, DC: Kaiser Family Foundation Kates J. 2004. Financing HIV/AIDS Care: A Quilt with Many Holes. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Kaiser Family Foundation.
327. Katz MH, Cunningham WE, Mor V, Andersen RM, Kellogg T, Zierler S, Crystal SC, Stein MD, Cylar K, Bozzette SA, Shapiro MF. 2000. Prevalence and predictors of unmet need for supportive services among HIV-infected persons: pmpact of case management. Medical Care 38(1):58-69.
328. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, McFarland W. 2002. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. American Journal of Public Health 92(3):388-394.
329. Kaye N, Cardona A. 2002. Trends in Serving People with HIV/AIDS through Medicaid Managed Care. 3rd edition. Portland, ME: National Academy for State Health Policy.
330. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. 1996. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. New England Journal of Medicine 334(11):701-706.
331. Kitahata MM, Van Rompaey SE, Sheilds AW. 2000. Physician experience in the care of HIVinfected persons is associated with earlier adoption of new antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome 24(2):106-114.
332. Laine C, Weinberg DS. 1999. How can physicians keep up-to-date? Annual Review of Medicine 50:99-110.
333. Levi J, Kates J. 2000. HIV: challenging the health care delivery system. American Journal of Public Health 90(7):1033-1036.
334. Levi J, Sogocio K, Gambrel A, Jones K. 1999. Can Access to the Private Individual Insurance Market be Increased for People Living with HIV? Washington, DC: George Washington University.
335. Levi J, Hidalgo J, Wyatt S. 2000. The Impact of State-by-State Variability in Entitlement Programs on the Ryan White CARE Act and Access to Services for Underserved Populations. Washington, DC: Health Resources and Services Administration.
336. Levi J, Parrish B, Miller V. 2003. Report of the December 10-11, 2002, Quality of Care- Closing the Gap Workshop. Washington, DC: George Washington University Center for Health Services Research and Policy.
337. Lewis CE. 1997. Management of patients with HIV/AIDS: who should care? Journal of the American Medical Association 278(14):1133-1134.
338. Lubinski C, Weddle A, Grayer C. 2002. Medicaid Financing of HIV Care: An analysis of Five State Programs. Paper prepared for the Committee on the Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Unpublished.
339. Manning WG, Newhouse JP, Duan N, Keeler EB, Leibowitz A, Marquis MS. 1987. Health insurance and the demand for medical care: Evidence from a randomized experiment. American Economic Review 77(3):251-277.
340. Marcus M, Freed JR, Coulter ID, Der-Martirosian C, Cunningham W, Andersen R, Garcia I, Schneider DA, Maas WR, Bozzette SA, Shapiro MF. 2000. Perceived unmet need for oral treatment among a national population of HIV-positive medical patients: social and clinical correlates. American Journal of Public Health 90(7):1059-1063.
341. MedPAC (Medicare Payment Advisory Commission). 2003. Assessing payment adequacy and updating payment for physician services. In: Report to the Congress: Medicare Payment Policy. Washington, DC: Medicare Payment Advisory Commission. Pp. 105-118.
342. Meyerson B, Chu BC, Mills MV. 2003. State agency policy and program coordination in response to the co-occurrence of HIV, chemical dependency, and mental illness. Public Health Reports 118(5):408-414.
343. Morin SF, Sengupta S, Cozen M, Richards TA, Shriver MD, Palacio H, Kahn JG. 2002. Responding to racial and ethnic disparities in the use of HIV drugs: analysis of state policies. Public Health Reports 117(3):263-272.
344. NASTAD (National Alliance of State and Territorial AIDS Directors). 2003. National ADAP Monitoring Project: Annual Report April 2003. [Online]. Available: http:// www.nastad.org/ADAP/adap2003.pdf [accessed March 5, 2004].
345. Newhouse JP and the Insurance Experiment Group. 1993. Free for All? Lessons from the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press.
346. New York State Department of Health, AIDS Institute. 2003. Designated AIDS Center Program Description and AIDS Intervention Management System, Program Description. New York: New York State Department of Health.
347. Norton S, Zuckerman S. 2000. Trends in Medicaid physician fees, 1993-1998. Health Affairs 19(4):222-232.
348. Perloff JD, Kleteke P, Fossett JW. 1995. Which physicians limit Medicaid participation, and why. Health Services Research 30(1):7-26.
349. Rice T. 2003. The impact of cost containment efforts on racial and ethnic disparities in healthcare: a conceptualization. In: Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC: National Academy Press. Pp. 699-721.
350. Rosenbaum S. 2003. Racial and ethnic disparities in healthcare: Issues in the design, structure, and administration of federal healthcare financing programs supported through direct public funding. In: Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press. Pp. 664-698.
351. Sambamoorthi U, Walkup J, Olfson M, Crystal S. 2000. Antidepressant treatment and health services utilization among HIV-infected Medicaid patients diagnosed with depression. Journal of General Internal Medicine 15(5):311-320.
352. Santerre RE. 2002. The inequity of Medicaid reimbursement in the United States. Applied Health Economics and Health Policy 1(1):25-32.
353. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. 2001. Costeffectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. American Journal of Public Health 91(9):1456-1463.
354. Shapiro MF, Ware JE Jr, Sherbourne CD. 1986. Effects of cost sharing on seeking care for serious and minor symptoms. Results of a randomized controlled trial. Annals of Internal Medicine 104(2):246-251.
355. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. 1999. Variations in the care of HIVinfected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association 281(24):2305-2315.
356. Sloan FJ, Cromwell J, Mitchelle, J. 1978. Private Physicians and Public Programs. Lexington, MA: D.C. Heath and Co.
357. SSA (Social Security Administration). 2004. Supplemental Security Income (SSI): Understanding Supplemental Security Income If You Are Disabled or Blind. [Online]. Available: http://www.ssa.gov/notices/supplemental-security-income/text-disable-ussi.htm [accessed February 3, 2004].
358. Stone VE, Mansourati FF, Poses RM, Mayer KH. 2001. Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. Journal of General Internal Medicine 16(6):360-368.
359. Tuller D. 2001, November 6. HIV practices face grim financial times. The New York Times. p. F6.
360. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, Stein MD, Longshore D, Bozzette SA. 2001. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine 16(9):625-633.
361. Valdez RO. 1986. The Effects of Cost Sharing on the Health of Children. Santa Monica, CA: RAND Corporation.
362. Valenti WM. 2002. The HIV specialist improves quality of care and outcomes. AIDS Reader 12(5):202-205.
363. Westmoreland T. 1999. Medicaid and HIV/AIDS Policy: A Basic Primer. Washington, DC: Henry J. Kaiser Family Foundation.
364. Wong MD, Andersen R, Sherbourne C, Hays RD, Shapiro MF. 2001. Effects of cost sharing on care seeking and health status: results from the Medical Outcomes Study. American Journal of Public Health 91(11):1889-1894.
365. Zuger A, Sharp VL. 1997. 'HIV specialists': the time has come. Journal of the American Medical Association 278(14):1131-1132.
366. Zweben JE. 2000. Severely and persistently mentally ill substance abusers: clinical and policy issues. Journal of Psychoactive Drugs 32(4):383-389.
367. APHA (American Public Health Association). 2003. Treatment Adherence to Anitretroviral Therapies: Recommendations for Best Practices. [Online]. Available: http://www.apha.org/ ppp/hiv [accessed March 22, 2004].
368. Ashman JJ, Conviser R, Pounds MB. 2002. Associations between HIV-positive individuals' receipt of ancillary services and medical care receipt and retention. AIDS Care 14:S109- S118.
369. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Robertson M, Zolopa AR, Moss A. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9):1181-1183.
370. Bodenheimer T, Wagner EH, Grumbach K. 2002. Improving primary care for patients with chronic illness. Journal of the American Medical Association 288(14):1775-1779.
371. Boyd DJ. 2003. The bursting state fiscal bubble and state Medicaid budgets. Health Affairs 22(1):46-61.
372. Cohn SE, Berk ML, Berry SH, Duan N, Frankel MR, Klein JD, McKinney MM, Rastegar A, Smith S, Shapiro MF, Bozzette SA. 2001. The care of HIV-infected adults in rural areas of the United States. Journal of Acquired Immune Deficiency Syndromes 28(4):385-392.
373. CDC (Centers for Disease Control and Prevention). 2001. Strategies for reducing morbidity and mortality from diabetes through health-care system interventions and diabetes selfmanagement education in community settings: a report on recommendations of the Task Force on Community Prevention Services. MMWR 50(RR-16):1-15. Atlanta, GA: CDC.
374. CMS (Centers for Medicare & Medicaid Services). 2003. Medicare General Information, Eligibility and Entitlement Manual. [Online]. Available: http://www.cms.hhs.gov/manuals/ 101_general/ge101index.asp [accessed February 20, 2004].
375. Davis M. 2002. Mental Illness and HIV Comorbidity: A Large and Vulnerable HIV Subpopulation. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: unpublished.
376. DHHS (U.S. Department of Health and Human Services). 2004. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. [Online]. Available: http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 [accessed March 23, 2004].
377. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30(1):105-110.
378. GAO (General Accounting Office). 2000. Ryan White CARE Act: Opportunities to Enhance Funding Equity. GAO/T-HEHS-00-150. Washington, DC: GAO.
379. GAO. 2001. Medicaid and SCHIP: States' Enrollment and Payment Policies Can Affect Children's Access to Care. GAO-01-883. Washington, DC: GAO.
380. Gifford AL, Groessl EJ. 2002. Chronic disease self-management and adherence to HIV medications. Journal of Acquired Immune Deficiency Syndromes 31:S163-S166.
381. IOM (Institute of Medicine). 2000. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press.
382. IOM. 2001a. No Time to Lose: Getting More from HIV Prevention. Washington DC: National Academy Press.
383. IOM. 2001b. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press.
384. IOM. 2002. Fostering Rapid Advances in Health Care: Learning from Systems Demonstration. Washington, DC: The National Academies Press.
385. IOM. 2003a. Priority Areas for National Action: Transforming Health Care Quality. Washington, DC: The National Academies Press.
386. IOM. 2003b. Measuring What Matters: Allocation Planning and Quality Assurance for the Ryan White CARE ACT. Washington, DC: The National Academies Press.
387. Kates J. 2004. Financing HIV/AIDS Care: A Quilt with Many Holes. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Kaiser Family Foundation.
388. Kates J, Marconi K, Mannle TE. 2001. Developing a performance management system for a federal public health program: the Ryan White CARE Act Titles I and II. Evaluation and Program Planning 24:145-155.
389. Laine C, Markson LE, Fanning TR, Turner BJ. 1999. Relationship between ambulatory care accessibility and hospitalization for persons with advanced HIV disease. Journal of Health Care for the Poor & Underserved. 10(3):313-327.
390. Lambrew J. 2001. Section 1115 Waivers in Medicaid and the State Children' Health Insurance Program an Overview. Washington DC: Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation.
391. Levi J. 2002. The Response of Programs That Finance HIV Care and Services to an Evolving Continuum of Services Needs for People Living with HIV. Paper prepared for the Committee on Public Financing and Delivery of HIV Care, Institute of Medicine. Washington, DC: Unpublished.
392. Levi J, Kates J. 2000. HIV: Challenging the health care delivery system. American Journal of Public Health 90(7):1033-1036.
393. Lo W, MacGovern T, Bradford J. 2002. Association of ancillary services with primary care utilization and retention for patients with HIV/AIDS. AIDS Care 14:S45-S57.
394. McKenna MT, Taylor WR, Marks, JS. 1998. Current issues and challenges in chronic disease control. In: Chronic Disease Epidemiology and Control. 2nd edition. Washington, DC: United Book Press. Pp. 1-26.
395. McNabb J, Ross JW, Abriola K, Turley C, Nightengale CH, Nicolau DP. 2001. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases 33(5):700-705.
396. MedPAC (Medicare Payment Advisory Commission). 2003. Assessing payment adequacy and updating payment for physician services. In: Report to the Congress: Medicare Payment Policy. Washington, DC: Medicare Payment Advisory Commission. Pp. 105-118.
397. Moore RD, Chaisson RE. 1997. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14(3): 223-231.
398. Moore RD, Chaisson RE. 1999. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 13(14):1933-1942.
399. NRC (National Research Council). 2001. Choosing the Right Formula: Initial Report. Washington, DC: National Academy Press.
400. New York State Department of Health. 1993. Supplement to DOH Memorandum 86-32 Update of Program Standards for Designated AIDS Center Hospitals. Health Facilities Series: H-22-93-25. Albany, NY: New York State Department of Health.
401. New York State Department of Health, AIDS Institute. No date. HIVQUAL Fact Sheet. Albany, NY: New York State Department of Health.
402. New York State Department of Health, AIDS Institute. 2003. Designated AIDS Center Program Description, and AIDS Intervention Management System, Program Description. Albany, NY: New York State Department of Health.
403. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338(13):853-860.
404. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD, HIV Outpatient Study Investigators. 2003. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Annals of Internal Medicine 138(8):620-626.
405. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133(1):21-30.
406. Ross DC, Cox L. 2003. Out in the Cold: Enrollment Freezes in Six State Children's Health Insurance Programs Withhold Coverage from Eligible Children. Washington, DC: Kaiser Commission on Medicaid and the Uninsured, Kaiser Family Foundation.
407. Shirk C. 2003. Shaping Public Programs through Medicare, Medicaid, and SCHIP Waivers: The Fundamentals. National Health Policy Forum Background Paper. Washington, DC, National Health Policy Forum, George Washington University.
408. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, Bing EG, Stein MD, Longshore D, Bozzette SA. 2001. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Journal of General Internal Medicine 16(9):625-633.
409. Wagner EH. 2001. Meeting the needs of chronically ill patients. British Medical Journal 323(7319):945-946.
410. Wagner EH, Austin BT, Von Korff M. 1996. Organizing care for patients with chronic illness. Milbank Quarterly 74(4):511-544.
411. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. 2001. Improving chronic illness care: translating evidence into action. Health Affairs 20(6):64-78.
412. Wheatly B. 2002. Issue Brief: Disease Management: Findings from Leading State Programs, Vol. 3, No. 3. Washington, DC: Academy Health State Coverage Initiatives.
413. Aldridge C, Doyle A. 2002. Issue Brief: AIDS Drug Assistant Programs: Getting the Best Price? National ADAP Monitoring Project. Washington, DC: Kaiser Family Foundation. Pp 1-8.
414. Altera T. 2001. Understanding the Dynamics of "Crowd-out": Defining Public/Private Coverage Substitution for Policy and Research. Washington, DC: Academy for Health Service Research and Health Policy.
415. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF. 1998. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. New England Journal of Medicine 339(26):1897-1904.
416. CDC (Centers for Disease Control and Prevention). 2003. HIV Diagnoses Climbing among Gay and Bisexual Men. Press Release, CDC Office of Communications.
417. Cohen-Ross D, Cox L. 2000. Making it Simple: Medicaid for Children and CHIP Income Eligibility Guidelines and Enrollment Procedures. Washington, DC: The Kaiser Commission on Medicaid and the Uninsured.
418. Cutler DM, Gruber J. 1996. Does public insurance crowd-out private insurance? Quarterly Journal of Economics, 8(2): 391-430.
419. DHHS (U.S. Department of Health and Human Services). 2000. AIDS Drug Assistance Program Cost Containment Strategies. OEI-05-99-00610. Washington, DC: DHHS Office of Inspector General.
420. DHHS. 2001. Cost Containment of Medicaid HIV/AIDS Drug Expenditures. OEI-05-99- 00611. Washington, DC: DHHS Office of Inspector General.
421. Dubay LC. 1999. Expansions in Public Health Insurance and Crowd-Out: What the Evidence Says. Washington, DC: Kaiser Family Foundation. Pp. 1-17.
422. Dubay LC, Kenney GM. 1997. Did the Medicaid expansions for pregnant women crowd-out private insurance? Health Affairs 16(1):185-193.
423. GAO (General Accounting Office). 2000. Federal Drug Discounts. GAO/T-HEHS-00-118. Washington, DC: GAO.
424. GAO. 2000. Ryan White CARE Act: Opportunities to Enhance Funding Equity. GAO/THEHS- 00-150. Washington, DC: GAO.
425. Graham JD. 1999. An investor's look at life-saving opportunities. Risk in Perspective. Harvard Center for Risk Analysis. [Online]. Available: http://www.hcra.harvard.edu/pdf/ February1999.pdf [accessed April 14, 2004].
426. Hammett TM, Gaiter JL, Crawford C. 1998. Reaching seriously at-risk populations: health interventions in criminal justice settings. Health Education and Behavior 25(1):99-120.
427. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. 2000. Willingness to pay for a quality-adjusted life year: in search of a standard. Medical Decision Making 20(3): 332-342.
428. Holahan J. 1997. Crowding-out: how big a problem? Health Affairs 16(1):204-206.
429. Holtgrave DR. 2004. Estimation of annual HIV transmission rates in the United States, 1978-2000. Journal of Acquired Immune Deficiency Syndromes 35(1):89-92.
430. HRSA (Health Resources and Services Administration). 2002. Title IV Services or Women, Infants, Children, Youth, and their Families. [Online]. Available: http://hrsa.gov/hab/ titleiv.htm [accessed April 14, 2004].
431. IOM (Institute of Medicine). 2000. To Err Is Human: Building a Safer Health System. Washington, DC: National Academy Press.
432. IOM. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press.
433. IOM. 2002. Fostering Rapid Advances in Health Care: Learning from Systems Demonstration. Washington, DC: The National Academies Press.
434. IOM. 2003a. Priority Areas for National Action: Transforming Health Care Quality. Washington, DC: The National Academies Press.
435. IOM. 2003b. Measuring What Matters: Allocation Planning and Quality Assurance for the Ryan White CARE ACT. Washington, DC: The National Academies Press.
436. Kahn JG, Haile B, Kates J, Chang S. 2001. Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. American Journal of Public Health 91(9):1464-1473.
437. Kahn JG, Zhang X, Cross LT, Palacio H, Birkhead GS, Morin SF. 2002. Access to and use of HIV antiretroviral therapy: variation by race/ethnicity in two public insurance programs in the U.S. Public Health Reports 117(3):252-262; discussion 231-232.
438. Kaiser Commission on Medicaid and the Uninsured. 2002. The Medicaid Resource Book: Eligibility, Benefits, Financing, Administration. Washington, DC: The Kaiser Commission on Medicaid and the Uninsured. Pp. 6-7.
439. Kronick R, Gilmer T. 2002. Insuring low-income adults: does public coverage crowd out private? Health Affairs 21(1):225-239.
440. Médecins Sans Frontières. 2003. Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries. [Online]. Available: http:// www.accessmed-msf.org/documents/untangling4thapril2003.pdf [accessed February 6, 2005].
441. MedPAC (Medicare Payment Advisory Commission). 2003. Report to the Congress: Medicare Payment Policy. Washington, DC: Medicare Payment Advisory Commission. Pp. 71-82.
442. Moon M, Friedland R, Shirley L. 2002. Medicare Beneficiaries and Their Assets: Implications for Low Income Programs. Washington, DC: Henry J. Kaiser Family Foundation.
443. Rich JD, Holmes L, Salas C, Macalino G, Davis D, Ryczek J, Flanigan T. 2001. Successful linkage of medical care and community services for HIV-positive offenders being released from prison. Journal of Urban Health 78(2):279-289.
444. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. 1996. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. Journal of the American Medical Association 276(14):1172-1177.
445. Sabin KM, Frey RL, Horsley R, Greby SM. 2001. Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998. Journal of Urban Health 78(2):241-255.
446. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA. 1999. Variations in the care of HIVinfected adults in the United States: results from the HIV Cost and Services Utilization Study. Journal of the American Medical Association 281(24):2305-2315.
447. Thorpe KE, Florence C. 1998. Health insurance coverage among children. The expanded medicaid coverage. Inquiry 35(4):369-379.
448. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. 1996. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Journal of the American Medical Association 276(15):1253-1258.
449. Wooldridge J, Hill I, Harrington M, Keeney G, Hawkes C, Hailey J, Bellamy H, Schwalberg, R. 2003. Interim Evaluation Report: Congressionally Mandated Evaluation of the State Children's Health Insurance Program. Washington, DC: Mathematica Policy Research.